31.73
+2.39%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immunocore Holdings
From its filings with the US Securities and Exchange Commission
Immunocore Holdings is based in Oxfordshire, United Kingdom and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker IMCR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $400.0m and a net loss of $35.5m. At that date it held total assets of $1.07bn and shareholders' equity of $381.0m.
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.
In 2022, we received approval for our lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma ("mUM") from the FDA, the European Commission and other health authorities. KIMMTRAK is now approved in 39 countries and the Company has commercially launched the product in 30 countries, including the United States, Germany and France, among other territories.
KIMMTRAK is the lead product from our ImmTAX platform and was the first approved therapy in mUM. To date, we have treated over 2,000 cancer patients with KIMMTRAK (tebentafusp), and our other ImmTAX product candidates, which we believe is the largest clinical data set of any T cell engager bispecific in solid tumors and any T cell receptor ("TCR") therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including melanoma, ovarian, lung, and colorectal, among others. We believe that these tumor types have large addressable patient populations and significant unmet need.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2021
- Employees
- 524
- Website
- immunocore.com ↗
- Head office
- 90 PARK DRIVE, OXFORDSHIRE, X0, OX14 4RY
- Incorporated in
- X0
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- KIMMTRAK treats unresectable or metastatic uveal melanoma patients effectively.
- Tebentafusp is in Phase 3 trials for advanced cutaneous melanoma.
- Brenetafusp targets first-line advanced cutaneous melanoma in Phase 3.
Weaknesses
- IMC-R117C is only in Phase 1/2 trials for solid tumors.
- IMC-P115C is in early Phase 1 for PRAME tumors.
- IMC-M113V is in Phase 1 for HIV functional cure.
Opportunities
- IMC-I109V targets hepatitis B virus functional cure in Phase 1.
- Expanding oncology programs covers various tumor types globally.
- Developing immunomodulating medicines for infectious diseases offers new markets.
Threats
- Competitors may develop similar immunomodulating medicines for cancer patients.
- Clinical trial failures could halt development of key programs.
- Regulatory hurdles might delay approval for new medicines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.